

Management of Status Epilepticus & Super-Refractory SE 2017

TAYARD DESUDCHIT MD.
HEAD, DIV. OF PED. NEUROLOGY
FACULTY OF MEDICINE
CHULALONGKORN U.

Definition SE

- Traditional : Prolonged seizure lasting ≥ 30 mins or series of seizure without full recovery to baseline lasting ≥ 30 mins
- Operational : Continuous seizures lasting at least 5 mins or two or more discrete seizures between which there is an incomplete recovery of consciousness
- NCSE : cognitive or behavior change (ranging from mild confusion to coma) coupled with EEG evidence of seizure

Definition SE

| Stage of SE | Duration (min) | |
|-------------|----------------|---|
| Premonitory | 0-5 | >90% seizure end spontaneously within 4 min |
| Early | 5-30 | Seizure lasting over 5min have over 90% probability to last over 30 min |
| Established | 30-60 | Criteria used in epidemiology |
| Refractory | >60 | Persistent seizure activity despite 1 st and 2 nd line Tx |

Epidemiology CSE

- Incidence of CSE : 10-38/100000 per year
- Bimodal distribution
 - highest in children (age 0-4years)
 - elderly
- Most common occurred in children less than 1 years
- Associated with poor socioeconomic

Classification of SE

- Generalized convulsive SE
 - Tonic
 - Tonic-clonic
 - Myoclonic
- Generalized nonconvulsive SE
 - Complex partial status
 - Absence status
- Focal SE
 - Epilepsia partialis continua (EPC)

Recommendation of Diagnostic evaluation of a child presenting in SE

| New onset SE | Known Epilepsy Patients |
|---|---|
| Always recommended <ul style="list-style-type: none"> - Electrolyte - EEG - CT/MRI | Always recommended <ul style="list-style-type: none"> - AED level |
| Clinical suspicion <ul style="list-style-type: none"> - Urine toxicology - Genetic/ Metabolic testing - LP | Consider <ul style="list-style-type: none"> - Electrolyte - EEG - CT/MRI |
| Add if Febrile <ul style="list-style-type: none"> - CBC / Hemoculture - LP | Consider if febrile <ul style="list-style-type: none"> - CBC / Hemoculture - LP |
| Refractory/Persistent encephalopathy <ul style="list-style-type: none"> - Video EEG monitoring | Refractory/Persistent encephalopathy <ul style="list-style-type: none"> - Video EEG monitoring |

Semin Pediatr Neurol 17:144-149

New onset SE : Imaging ??

- CT/MRI
 - Imaging abnormality 13% to 32%
 - MRI greater sensitivity for cerebral dysgenesis and other cerebral malformation
 - CT scanning may be used in an emergency setting.

Semin Pediatr Neurol 17:144-149

New onset SE : EEG ??

- EEG
 - Characterize status : Focality
 - Epileptiform discharge
 - Generalise slow
 - Identify : NCSE
- NCSE
 - After CSE were found to be in NCSE 22%
 - Subclinical seizure 4%

Semin Pediatr Neurol 17:144-149


Treatment

- Termination of seizure
- Prevention of seizure recurrence
- Management of precipitating causes
- Management of complication

Treatment : Stabilize patient


- ABCDE
 - Maintain Airway
 - Breathing : Oxygen / Intubation
 - Circulation : IV access
 - Dextrose
 - Electrolyte : Na Ca Mg PO₄ and AED level

Stage of treatment SE



Brain 2011; 134; 2802-2818

Mayo Clinic



Boston Children's hospital

- 5 minutes:** Lorazepam, 0.1 mg/kg (usual maximum dose 4 mg/dose); if no IV access, diazepam, 0.5 mg/kg/dose (maximum 20 mg/dose) per rectum
- 10-15 minutes:** Lorazepam, 0.1 mg/kg/dose and start fosphenytoin, 20 mg PE/kg/dose
If fosphenytoin is not available, use phenytoin 20 mg/kg
- 15-20 minutes:** If seizures persist, phenobarbital 20 mg/kg dose
- 20-30 minutes:** If seizures persist, fosphenytoin, 10 mg PE/kg
- Consider pyridoxine (Vitamin B₆) for infants and children, especially with underlying epilepsy.



Treatment

- 0-5 min** : Oxygen, Airway, Position, Vital sign, IV line
Investigation
- 6-30 min** : IV glucose / Thiamine / Pyridoxine 100 mg
Diazepam 0.3-0.5 mg/kg/dose
Phenytoin 20 mg/kg/dose
Phenobarbital 20 mg/kg/dose
Sodium Valproate 20 mg/kg/dose
Levetiracetam 20 mg/kg/dose
- 30+ min** : Add PHT/ PB / VPA
- 60+ min** : Midazolam 200 mcg/kg/dose bolus

(Epilepsy Society of Thailand 2011)

Termination of seizure

| Drug | Dose&Route | Onset | Duration |
|-----------|--|--------------------------------------|-----------|
| Diazepam | 0.3 mg/kg IV in 2-5 min 0.5 mg/kg Rectal Max 10 mg | 1-3 min Highly lipid soluble | 15-30 min |
| Midazolam | 0.2 mg/kg IM/ IV 0.5 mg/kg Buccal / IN Max 10 mg | Fast acting water soluble 3-5 min | 2-6 hr |
| Lorazepam | 0.1 mg/kg IV Max 4 mg | 6-10 min | 12-24 hr |

Transmucosal pharmacological therapy



- Intranasal midazolam as effective as intravenous diazepam
- Buccal midazolam as effective as rectal diazepam.
- Intravenous formulations of midazolam (given buccal or intranasal routes) are relatively inexpensive.
- Caregivers prefer intranasal midazolam to rectal diazepam.

Appleton R et al Cochrane Database Syst Rev 2008 Jul 16;(3)

Prevention of recurrence seizure

| Drug | Dosage&Route | Rate of infusion | Precaution |
|---------------|----------------|---|---|
| Phenytoin | 20 mg/kg IV | 1 mg/kg/min (50 mg/min) Dilute NSS Only | Phlebitis (pH 11-12) Hypotension Arrhythmia |
| Phenobarbital | 20 mg/kg IV | 3 mg/kg/min | Sedation Apnea Hypotension |
| Valproate | 20 mg/kg IV | 3-6 mg/kg/min | Liver disease Thrombocytopenia Hyperammonemia |
| Levetiracetam | 20 mg/kg IV | Rapid infusion | |
| Fosphenytoin | 20 mg/kg IV/IM | 3 mg/kg/min | Prodrug of PHT pH 8-9 |

Treatment SE




Figure 5.

Staged approach to the treatment of convulsive status epilepticus. *There is currently limited evidence for the use of lacosamide in SE (see Häfner et al., 2011) Modified after Trinka, 2007; Shorvon et al., 2008.

Epilepsia © ILAE

Epilepsia, 53(Suppl. 4):127-138, 2012
doi: 10.1111/j.1528-1167.2012.03622.x

Purple Glove syndrome



Treatment of refractory SE

- No prospective randomised trials comparing the effects of anesthetics in the treatment of RSE.
- Safety data lacking.

Options:

- Barbiturate anesthetics: Pentobarbital (US)
Thiopental (Europe Aus)
- Propofol
- Midazolam.
- Evidence based medicine: No recommendations on data available.
- Even in a large survey of neurologists in USA – little consensus for 3rd / 4th line intervention (*J Neurol Sci* 2003)

Rosenow et al; *Epileptic Disord* 2002

Midazolam

- Standard dosage Midazolam
 - Loading dose 0.2 mg/kg (200 mcg/kg/dose)
 - maintained at 0.1 to 0.6 mg/kg/hr.
- (2 mcg/kg/min titrate every 15 min to 10 mcg/kg/min)
- Half-life of 6 to 40 h after prolonged infusion.
- Main drug interactions : None.
- Main side effects : Sedation
Respiratory depression
Hypotension → Inotropic drug

Brain 2011; 134: 2802-2818

Midazolam infusion

- Requires a syringe driver
- Greater risk of airway suppression (especially following previous Benzo boluses)
- Takes long time to gain control (range 15 mins – 4.5 hours)
- Potential for children left with prolonged seizures and irreversible neuronal cell death in centres without high care facilities
- **NOTE: Excluded from APLS guidelines**

Rivera et al; *CCM* 1993
Lal Koul et al; *ARCH* 1997
Ozdemir et al; *Seizure* 2005

Thiopentone

- Poor anticonvulsant
- Marked haemodynamic effects
- Prolonged drug effects if infusion used
- Local ICU capacity limited
- **Staffing**
- **Monitoring**
- **Anaesthetic experience**

Very-high-dose Phenobarbitone

- Both barbiturates and benzodiazepines exert a primary effect on the GABA receptor complex.
- No antiepileptic ceiling effect ! No maximum dose beyond which further doses are likely to be ineffective >200 mg/kg!

Complications:

- Sedative and respiratory-depressant properties more likely in combination with benzodiazepines.
- Hypotension unusual and related to the highest Phenobarbitone levels and easily controllable.
- Complications usually related to underlying aetiology

Crawford et al; Neurol 1988

Intravenous Sodium Valproate

- FDA approved 1996.
- Not in APLS guidelines
- No reports of respiratory depression or hypotension.
- Caution in children with underlying liver disease or suspected mitochondrial disorder.
 - Potential hepatic encephalopathy
- Comparative studies:
 - Intravenous Sodium Valproate vs Diazepam infusion
 - Intravenous Sodium Valproate vs Phenytoin.
- No large studies measuring efficacy
- Larger paediatric focused studies are needed
- Still need syringe driver
- Very expensive
- Drug of choice: Absence status

Linnik et al; Neurology 2002
Ravitsky & Shorofsky; Neurology 2002
Linnik et al; Neurology 2002
Ravitsky & Shorofsky; Neurology 2002
Linnik et al; Neurology 2002

IV Levetiracetam

- FDA approved adults over 16 yrs since 2006
- Limited data in children (most retrospective case reviews – n=10 and n=32)
- Loaded with 25-50mg/kg at level 3
- Effective
- Safe
- Larger comparison studies needed

Kirmani et al Ped Neurol 2009
Abend et al Pediatr Crit Care Med 2009
Gamez-Leyva et al CND Drugs 2009

Why is IV phenobarbitone so good for resource poor countries?

- Highly effective at controlling status
- Safe
- Cheap
- It can be given by rapid IV bolus
- It can be repeated
- It can be given by IM route
- No need for syringe driver
- If control not attained at 1 hour time to arrange transfer to tertiary unit – exceptional situation

Crawford et al; Neurol 1988;
Wilmschurst & Newton; DMCN 2005
Lee et al; Pediatr Neurol 2005

Lacosamide

- Adult :Bolus dose 400 mg (range 200–400 mg), Rate 40–80 mg/min
 - Success Rate 1st/2nd AED: 3/5, 3rd AED: 11/19, >= 4th AED :3/15 Failed in 5 subjects, No serious adverse events
 - 2008-2016 review: 522 SE (486 adults /36 children); overall LCM efficacy 57%; comparable in nonconvulsive and generalized-convulsive (57%/61%);
 - Better in focal motor SE (92%; p = 0.013; p < 0.001).
 - If LCM used as later AED: Eff drop from 100% ->20%.
 - AE : dizziness, abnormal vision, diplopia, and ataxia.
- Pediatric: Bolus 8.7 mg/kg(up to 10 mg/kg), Total first 24 hour 13.8 mg/kg
 - Success 77.8%(7/9), Sz free 44.4 (4/9), failed 2/9
 - 30% to 50% of children experienced at least a 50% reduction in seizure frequency, similar to results obtained in clinical trials in adults. Children with focal onset seizures were most likely to benefit from treatment

Kellinghaus et al; Acta Neurol Scand 2010;
Strzelczyk et al; Epilepsia 2017;
Poddar et al; j.pediatrneurol.2016.

What to do when Midazolam drip failed ?

Duration of therapy: Pharmacologic coma duration should be determined and is often 24-48 hours, with exact determination made by considering seizure response, underlying etiology management, and time required to initiate or modify other anti-seizure medications. The wean time should be determined and is often 24-48 hours, with exact determination made by considering EEG monitoring data during wean and systemic adverse effects.

Goals of therapy: Burst suppression vs. termination of status epilepticus vs. termination of all electrographic seizures. The goal depends on the patient-specific clinical factors as well as the drug being used (e.g. different for certain general anesthetics like Ketamine).


Criteria for transitioning to or adding additional coma-inducing agents: If seizures persist after 4 hours, on high-infusion doses, or adverse effects occur, then transition to additional medications may be appropriate. If seizures are somewhat improved but persist or adverse effects are developing, then addition of an additional medication may be appropriate.

- Patients < 10 kg: Choose Midazolam 1 mg/mL concentration at the initiation of the titration protocol. After escalating over 4 hours, change the concentration to 5 mg/mL.
- For patients on the ketogenic diet, ensure that the diluent is normal saline.

Outcome and Prognosis SE

- Factor determine risk of mortality and morbidity
 - Certain etiology
 - Age
 - Long duration of SE
- Mortality rates
 - Short term during the first 30-60 days after SE mortality rate 7-25%
 - unprovoked or febrile CSE 0.2%
 - acute symptomatic CSE 12.5-16%


F 10 Year Old Mida 12 mic / Propafol 4/Acidosis




F 10 Year Old Mida 12 mic / Propafol 4/Acidosis

- Midazolam bolus 0.2 mg/kg -> No changes
- Already on Ketogenic diet, urine ketone 2+
- Tx from Saraburi on Pheno/VPA bl level 150/9 mg/kg/min
- On Propofol to max 10 mic/kg/min -> developed acidosis / CPK 500 / drop propofol -> Sz recurred
- Phenobarbital level 102 mg/dl
- What Would you like to do ?
- Bolus 5 mg/ 1st dose : no changes
- Bolus 5 mg/ 2nd dose : Burst Suppress ☺


F 10 Year Old Mida 12 mic / Propafol 4/Acidosis






Just before next dose : Observation



It's OK : Continue Observation



Add 2mg/kg IV Phenobarbital Bolus



Neurologic sequelae

- Secondary epilepsy
- Cognitive deterioration
- Behavioral problems
- Focal neurologic deficit

doi:10.1093/brain/aww091

Brain 2012; 135, 2314–2328 | 2314

BRAIN
 A JOURNAL OF NEUROLOGY

REVIEW ARTICLE

The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy

Simon Shorvon and Monica Ferlisi

Table 1 The published literature on treatment outcomes

| Therapy | Number of published papers reporting outcome data | Number of published cases in which outcome data are provided |
|---------------------------|---|--|
| Pentobarbital/thiopental | 23 | 192 |
| Propofol | 24 | 143 |
| Midazolam | 20 | 585 |
| Ketamine | 7 | 17 |
| Inhalational anaesthetics | 7 | 27 |
| Hypothermia | 4 | 9 |
| Magnesium | 2 | 3 |
| Pyridoxine | 2 | 2 |
| Immunotherapy | 8 | 21 |
| Ketogenic diet | 4 | 14 |
| Vagal nerve stimulation | 4 | 4 |
| Deep brain stimulation | 1 | 1 |
| ECT | 6 | 8 |
| Emergency neurosurgery | 15 | 36 |
| CSF drainage | 1 | 2 |
| Topiramate | 10 | 60 |
| Levetiracetam | 8 | 35 |
| Pregabalin | 1 | 2 |
| Lacosamide | 2 | 10 |

Table 2 Overall outcome of anaesthetic therapy

| Outcome | Thiopental/pentobarbital (n = 192) | Midazolam (n = 585) | Propofol (n = 143) |
|---|---------------------------------------|------------------------|-----------------------|
| Control | 64% (123/192) | 78% (458/585) | 68% (97/143) |
| No control ever achieved ^a | 5% (9/192) | 16% (93/585) | 11% (16/143) |
| Breakthrough seizures | 0% (0/192) | 3% (19/585) | 1% (2/143) |
| Withdrawal seizures | 9% (18/192) | <1% (2/585) | 6% (8/143) |
| Therapy failure because of side-effects | 3% (5/192) | <1% (1/585) | 6% (8/143) |
| Death during therapy | 19% (37/192) | 2% (12/585) | 8% (12/143) |

^aExcluding those who died without control who are included in the 'death during therapy' category, and those who switched because of side-effects who are included in the 'therapy failure because of side-effects' category.

Table 3 Long-term outcome

| Outcome ^a | n = 596 |
|--------------------------------|-----------|
| Deaths | 207 (35%) |
| Severe neurological deficit | 79 (13%) |
| Mild neurological deficit | 80 (13%) |
| Undefined neurological deficit | 22 (4%) |
| Recovery to baseline | 208 (35%) |

^aIn the reports of 596 cases (51% of the total of 1168), the long-term outcome was recorded. In the other 575 cases, no long-term outcome data were provided.

Refractory SE ??

- Review diagnosis : True seizure ??
 - Abnormal movement
 - Psychogenic nonepileptic seizures
- Review Treatment : Adequate ??

Differential diagnosis of CSE

- Tonic extensor spasm
 - tentorial herniation
 - acute brainstem dysfunction
- Acute dystonic reaction
- Chorea
- Paroxysmal dyskinesia
- Psychogenic status epilepticus

Clinical features of epileptic seizures versus psychogenic nonepileptic seizures

| Clinical feature | Epileptic seizures | Psychogenic nonepileptic seizures |
|--------------------------|--------------------|-----------------------------------|
| Eye closed | Uncommon | Very common |
| Stereotyped Sz semiology | Common | Less common |
| Sz duration > 2 mins | Uncommon | common |
| Sz onset at sleep | Common | Uncommon |
| Enuresis | Common | Uncommon |
| Injury | Common | Uncommon |
| Medial tongue bite | Common | Uncommon (Tip of tongue) |

C.E. Elger, D. Schmidt / *Epilepsy & Behavior* 12 (2008) 501–539

Refractory SE

- Consult : neurologist
- EEG Monitoring
- Look for treatable cause : autoimmune encephalitis
- Refer

Brain Monitoring

- Continuous
- Non-invasive
- Highly sensitive to a variety of brain insults
- Reasonably specific
- User friendly
- Not too expensive!

Kurtz et al Curr Opin Crit Care 2009


Monitoring

cEEG (continuous EEG – full head montage)

- The Gold standard – not viable in most SA settings
- Non-convulsive seizures
- Ischaemia

aEEG (Amplitude-integrated EEG)

- Assessing if burst suppression attained
- Non-convulsive seizures
- Potential artefact
- Need to remember overall underlying cause usually the defining feature for the outcome of the child.




Case Report

A case of frontal lobe epilepsy in which amplitude-integrated EEG combined with conventional EEG was useful for evaluating clusters of seizures

Nobutsune Ishikawa*, Yoshiyuki Kobayashi, Masao Kobayashi

Epilepsy & Behavior 18 (2010) 485–487

Department of Pediatrics, Nihon University Graduate School of Biomedical Sciences, Niihama, Japan



ABSTRACT

Accurate evaluation of status epilepticus or clusters of seizures in patients with epilepsy is a critical issue in epilepsy care units. Although the need for continuous electroencephalographic monitoring has been recognized, it has been difficult to evaluate the frequency of ictal changes in electroencephalography (EEG) data in real time. Amplitude-integrated EEG (aEEG) has been reported to be useful for neonatal monitoring, particularly in newborn infants. However, few reports of the utility of aEEG in older children with epilepsy have been published. We employed aEEG in combination with conventional EEG in an 11-year-old boy presenting with clusters of seizures and were able to accurately evaluate the frequency of seizures in real time. The combination of aEEG and conventional EEG may be a useful tool in both neonatal intensive care units and epilepsy care units.







© 2010 Elsevier Inc. All rights reserved.


Non Pharmacological Rx : SRSE

- Ketogenic Diet
- IV Methyl Prednisolone (In specific cases)
- IVIG
- Surgical Resection
- VNS
- (Case to be presented during the meeting)


Ketogenic Diet : PT

- A 10 year old Thai female
 - Intractable left frontal lobe seizure since age of 4 year old
 - Medications :
 - Functions : Can do all activity of daily living by herself but slow & never go to school : IQ 68
 - Developed Status Epilepticus → Intubated → PHT/Phenobarbital/VPA/Midazolam IV
 - Transferred to the ward with IV Midazolam





- Ketogenic Diet Started -> seizure subside in one week, urine ketone 2-3 +
- The patient was seizure free x 3 months then developed rare nocturnal seizures
- She refused to take ketogenic diet after one year !-> readmitted with status epilepticus
- Left frontal lobe resection -> Partial improvement
- Zonisgran was started with ketogenic diet
- Require constant dose adjustment



Functional Hemispherectomy


- PK : A Nine year old Thai boy who was previously healthy
- Two years ago he developed right hand and finger abnormal movement which gradually stopped spontaneously
- Developed seizure with no fever in Dec 2013, received PHT -> well controlled x 1 1/2 months.
- Developed fever with Rash -> PHT was stopped
- Rt side clonic seizures recurred and gradually become continuous in two weeks.-> Intubated -> Rx in ICU







- DDx Mitochondria
- Transferred to chula via 12 hours ambulance from Songkhla


| Hour | 2:00 | 4:00 | 6:00 | 8:00 | 10:00 | 12:00 | 14:00 | 16:00 | 18:00 | 20:00 | 22:00 | 24:00 |
|----------------------|------|------|------|------|-------|-------|-------|-------|-------|-------|-------|-------|
| 1. Temperature | | | | | | | | | | | | |
| 2. Heart rate | | | | | | | | | | | | |
| 3. Blood pressure | | | | | | | | | | | | |
| 4. Oxygen saturation | | | | | | | | | | | | |
| 5. Glucose | | | | | | | | | | | | |
| 6. Urine output | | | | | | | | | | | | |
| 7. Seizure activity | | | | | | | | | | | | |
| 8. Caloric intake | | | | | | | | | | | | |
| 9. Fluid intake | | | | | | | | | | | | |
| 10. Weight | | | | | | | | | | | | |
| 11. Complications | | | | | | | | | | | | |

EEG Monitoring Focal SE (EPC)









- CFM -> Titration of Keppra, Phenobarb up and add lacosamide
- Seizure improved, regain consciousness but Rt side EPC persisted.



EEG Monitoring Focal SE



MRI Jan 2014 vs Feb 2014



S/P Left Functional Hemispherectomy



- Repeat MRI Obtained -> Progressive increased in T2 changes
- Dx : Rasmussen encephalitis
- > Lt functional hemispherectomy

